Please use this identifier to cite or link to this item: https://doi.org/10.1186/cc10307
Title: Levosimendan inhibits release of reactive oxygen species in polymorphonuclear leukocytes in vitro and in patients with acute heart failure and septic shock: A prospective observational study
Authors: Hasslacher, J
Bijuklic, K
Bertocchi, C 
Kountchev, J
Bellmann, R
Dunzendorfer, S
Joannidis, M
Keywords: dobutamine
formylmethionylleucylphenylalanine
levosimendan
noradrenalin
phorbol 13 acetate 12 myristate
reactive oxygen metabolite
cardiotonic agent
hydrazone derivative
pyridazine derivative
reactive oxygen metabolite
simendan
acute heart failure
adult
aged
apoptosis
article
clinical article
continuous infusion
controlled study
drug blood level
female
flow cytometry
heart hemodynamics
human
human cell
in vitro study
kidney function
male
neutrophil
observational study
priority journal
prospective study
protein expression
septic shock
acute disease
Austria
drug antagonism
drug effect
heart failure
middle aged
pathophysiology
septic shock
Acute Disease
Aged
Aged, 80 and over
Austria
Cardiotonic Agents
Female
Flow Cytometry
Heart Failure
Humans
Hydrazones
Male
Middle Aged
Neutrophils
Prospective Studies
Pyridazines
Reactive Oxygen Species
Shock, Septic
Issue Date: 2011
Citation: Hasslacher, J, Bijuklic, K, Bertocchi, C, Kountchev, J, Bellmann, R, Dunzendorfer, S, Joannidis, M (2011). Levosimendan inhibits release of reactive oxygen species in polymorphonuclear leukocytes in vitro and in patients with acute heart failure and septic shock: A prospective observational study. Critical Care 15 (4) : R166. ScholarBank@NUS Repository. https://doi.org/10.1186/cc10307
Rights: Attribution 4.0 International
Abstract: Introduction: Levosimendan is an extensively investigated inodilator showing also cardioprotective and antiinflammatory effects. The aim of our study was to explore the influence of levosimendan on polymorphonuclear leucocytes (PMN), a main source of reactive oxygen species, in vitro and in patients with acute heart failure or septic myocardial depression.Methods: PMN isolated from healthy volunteers were incubated with levosimendan in vitro. After stimulation with N-formyl-Met-Leu-Phe (fMLP) or phorbol 12-myristate 13-acetate (PMA) respiratory burst was quantified using a fluorescent dye. Apoptosis and expression of cell adhesion molecules of PMN were measured by flow cytometry. For determination of in vivo effects patients with acute heart failure (n = 16) or septic cardiac failure (n = 9) receiving levosimendan treatment were enrolled consecutively. PMN were isolated to measure respiratory burst activity before treatment as well as one and two hours after initiation of levosimendan administration. Furthermore inflammatory, hemodynamic and renal function parameters were obtained.Results: In vitro, levosimendan suppressed respiratory burst activity in fMLP or PMA stimulated PMN in a dose dependent manner by 30 ± 11% (P < 0.001) at 100 ng/mL and by 27 ± 17% (P < 0.001) at 1000 ng/mL respectively. Markers of apoptosis and PMN cell adhesion molecule expression remained unaffected by levosimendan treatment.In vivo, levosimendan treatment for two hours resulted in a significant reduction of PMA stimulated oxidative burst by 45% (P < 0.01) and fMLP stimulated oxidative burst by 49% (P < 0.05) in patients with acute heart failure. In patients suffering from septic shock levosimendan treatment decreased oxidative burst activity in unstimulated, fMLP and PMA stimulated PMN by 48% (P < 0.05), 46% (P < 0.01) and 43% (P < 0.01) respectively.Conclusions: Levosimendan appears to exert distinct immunomodulatory effects by decreasing oxidative burst activity of PMN. This property might contribute to the previously described cardioprotective effects of the drug. © 2011 Hasslacher et al.; licensee BioMed Central Ltd.
Source Title: Critical Care
URI: https://scholarbank.nus.edu.sg/handle/10635/180856
ISSN: 1364-8535
DOI: 10.1186/cc10307
Rights: Attribution 4.0 International
Appears in Collections:Staff Publications
Elements

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1186_cc10307.pdf488.23 kBAdobe PDF

OPEN

NoneView/Download

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons